These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 31746315

  • 1. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
    Xia W, Mao W, Chen R, Lu R, Liu F, He Y, Wang S, Li X, Zheng M.
    Med Sci Monit; 2019 Nov 20; 25():8764-8776. PubMed ID: 31746315
    [Abstract] [Full Text] [Related]

  • 2. Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Takashima Y, Sakakibara-Konishi J, Hatanaka Y, Hatanaka KC, Ohhara Y, Oizumi S, Hida Y, Kaga K, Kinoshita I, Dosaka-Akita H, Matsuno Y, Nishimura M.
    Clin Lung Cancer; 2018 Jul 20; 19(4):352-359.e1. PubMed ID: 29544718
    [Abstract] [Full Text] [Related]

  • 3. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G, Li Y, Shi R, Xu S, Zhang Z, Cao P, Chen C, Liu H, Chen J.
    Zhongguo Fei Ai Za Zhi; 2021 Apr 20; 24(4):236-244. PubMed ID: 33910272
    [Abstract] [Full Text] [Related]

  • 4. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Kita K, Fukuda K, Takahashi H, Tanimoto A, Nishiyama A, Arai S, Takeuchi S, Yamashita K, Ohtsubo K, Otani S, Yanagimura N, Suzuki C, Ikeda H, Tamura M, Matsumoto I, Yano S.
    Cancer Sci; 2019 Oct 20; 110(10):3215-3224. PubMed ID: 31432603
    [Abstract] [Full Text] [Related]

  • 5. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X.
    Clin Lung Cancer; 2015 Sep 20; 16(5):e25-35. PubMed ID: 25801750
    [Abstract] [Full Text] [Related]

  • 6. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
    Ding Y, Zhang L, Guo L, Wu C, Zhou J, Zhou Y, Ma J, Li X, Ji P, Wang M, Zhu W, Shi C, Li S, Wu W, Zhu W, Xiao D, Fu C, He Q, Sun R, Mao X, Lizaso A, Li B, Han-Zhang H, Zhang Z.
    Thorac Cancer; 2020 Jan 20; 11(1):103-112. PubMed ID: 31692283
    [Abstract] [Full Text] [Related]

  • 7. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
    Fang X, Li D, Wan S, Hu J, Zhang P, Jie D, Chen L, Jiang G, Song N.
    J Gene Med; 2024 Jun 20; 26(6):e3694. PubMed ID: 38847309
    [Abstract] [Full Text] [Related]

  • 8. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL, He RQ, Zhang Y, Wei DM, Hu XH, Chen G.
    Int J Oncol; 2018 Oct 20; 53(4):1557-1579. PubMed ID: 30066858
    [Abstract] [Full Text] [Related]

  • 9. An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    Cheng C, Zhao Y, Schaafsma E, Weng YL, Amos C.
    Int J Cancer; 2020 Nov 01; 147(9):2621-2633. PubMed ID: 32406930
    [Abstract] [Full Text] [Related]

  • 10. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
    Li LC, Chen XW, Fang L, Jian CL, Yu YX, Liao XY, Sun JG.
    Can Respir J; 2023 Nov 01; 2023():4689004. PubMed ID: 37388902
    [Abstract] [Full Text] [Related]

  • 11. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC, Jablons DM, Yang CT, You L.
    Int J Mol Sci; 2019 Aug 05; 20(15):. PubMed ID: 31387256
    [Abstract] [Full Text] [Related]

  • 12. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M, Mukhopadhyay M, Das C, Chatterjee S, Naskar BG.
    J Cancer Res Ther; 2021 Aug 05; 17(6):1389-1396. PubMed ID: 34916369
    [Abstract] [Full Text] [Related]

  • 13. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.
    J Thorac Oncol; 2011 Apr 05; 6(4):707-15. PubMed ID: 21258250
    [Abstract] [Full Text] [Related]

  • 14. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL.
    J Thorac Oncol; 2018 Dec 05; 13(12):1884-1896. PubMed ID: 30267840
    [Abstract] [Full Text] [Related]

  • 15. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK, Lee HY, Ahn MJ, Choi YL, Lee JH, Park K, Lee KS.
    Clin Lung Cancer; 2015 May 05; 16(3):228-36. PubMed ID: 25499173
    [Abstract] [Full Text] [Related]

  • 16. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
    Wang T, Liu Y, Zhou B, Hao S, Wang Z, Liang N, Liu J, Wang S.
    Indian J Cancer; 2017 May 05; 54(1):215-222. PubMed ID: 29199694
    [Abstract] [Full Text] [Related]

  • 17. Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Formalin Fixed Paraffin Embedded Tissue by Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) in Non-Small Cell Lung Cancer in the Northeastern Region of Thailand.
    Saiyaros K, Kritpetcharat P, Pairojkul C, Sithithaworn J.
    Asian Pac J Cancer Prev; 2019 May 25; 20(5):1339-1343. PubMed ID: 31127887
    [Abstract] [Full Text] [Related]

  • 18. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
    Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X, Zhao S, Zheng Q, Pan H, Zhang L, Long H, Yang H, Wang X, Wen Z, Wang J, Yang H, Xia X, Zhao Y, Hou X, Ma Y, Zhou T, Zhang Z, Zhan J, Huang Y, Zhao H, Zhou N, Yi X, Zhang L.
    Mol Cancer; 2019 Jan 09; 18(1):7. PubMed ID: 30626401
    [Abstract] [Full Text] [Related]

  • 19. Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.
    Nosaki K, Satouchi M, Kurata T, Yoshida T, Okamoto I, Katakami N, Imamura F, Tanaka K, Yamane Y, Yamamoto N, Kato T, Kiura K, Saka H, Yoshioka H, Watanabe K, Mizuno K, Seto T.
    Lung Cancer; 2016 Nov 09; 101():1-8. PubMed ID: 27794396
    [Abstract] [Full Text] [Related]

  • 20. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
    Zhang Y, Wang Q, Han ZG, Shan L.
    Asian Pac J Cancer Prev; 2013 Nov 09; 14(5):2879-83. PubMed ID: 23803047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.